Piperidine-based heterocyclic oxalyl amides as potent p38α MAP kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 1059-1062

  Mavunkel, Babu J ^a   Perumattam, John J ^a   Tan, Xuefei ^a   Luedtke, Gregory R ^a   Lu, Qing ^a   Lim, Don ^a   Kizer, Darin ^a   Dugar, Sundeep ^a   Chakravarty, Sarvajit ^a   Xu, Yong jin ^a   Jung, Joon ^a   Liclican, Albert ^a   Levy, Daniel E ^a   Tabora, Jocelyn ^a  

^a SCIOS INC   (United States)

Author keywords

Amide; Heterocyclic; Inflammatory; Inhibitor; Kinase; MAP; Oxalyl; p38; Piperidine

Indexed keywords

AMIDE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PIPERIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; HETEROCYCLIC COMPOUND; OXALIC ACID DERIVATIVE; PIPERIDINE; PROTEIN KINASE INHIBITOR;

ARTICLE; CELL ASSAY; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG SYNTHESIS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPARATIVE STUDY; HUMAN; METABOLISM; X RAY CRYSTALLOGRAPHY;

AMIDES; CRYSTALLOGRAPHY, X-RAY; HETEROCYCLIC COMPOUNDS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 14; OXALATES; PIPERIDINES; PROTEIN KINASE INHIBITORS;

EID: 74049148916     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.12.031     Document Type: Article

References (26)

1. Smolen J.S., and Steiner G. Nat. Rev. Drug Disc. 2 (2003) 473
2. Smith R.J. Drug Discovery Today 10 (2005) 1598
3. Cominelli F. N. Eng. J. Med. 351 (2004) 2045
4. Sticherling M. Drug Discovery Today 2 (2005) 275
5. Jarvis B., and Faulds D. Drugs 57 (1999) 945
6. Choy E.H., and Panayi G.S. N. Eng. J. Med. 344 (2001) 907
7. Lichtenstein G.R., Panaccione R., and Mallarkey G. Ther. Adv. Gastroenterol. 1 (2008) 43
8. Furst D.E. Clin. Ther. 26 (2004) 1960
9. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNutly D., Blumenthal M.J., Heyes J.R., Landvatter S.W., Strickler J.E., McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., Adams J.L., and Young P.R. Nature 372 (1994) 739
10. Foster M.L., Halley F., and Souness J.E. Drug News Perspect. 13 (2000) 488
11. Kumar S., Boehm J., and Lee J.C. Nat. Rev. Drug Disc. 2 (2003) 717
12. Saklatvala J. Curr. Opin. Pharmacol. 4 (2004) 372
13. Dominguez C., Powers D.A., and Tamayo N. Curr. Opin. Drug Discov. Devel. 8 (2005) 421
14. Lee M., and Dominguez C. Curr. Med. Chem. 12 (2005) 2979
15. Mavunkel, B. J.; Chakravarty, S.; Perumattam, J. J.; Luedtke, G. R.; Lu, Q.; Dugar, S.; Laney, M.; Henson, M.; Protter, A.; Xu, Y.-J.; Schreiner, G. F.; Almirez, R.; Scott, B.; Lewicki, J.; Moore, A.; Lee, S.; Brahn, E.; Liu, D. Y. International Symposium on Advances in Synthetic, Combinatorial and Medicinal Chemistry, Moscow, Russia, 2004.
16. Docking studies were conducted using a high-resolution p38α X-ray structure (PDB ID: 1ove). The extra-precision mode of Glide, a ligand-receptor docking tool (Schrodinger, LLC), was used to generate a poses for piperidine indole analog 1. Poses were further filtered by visual inspection.
17. Davies S.P., Reddy H., Caivano M., and Cohen P. Biochem. J. 351 (2000) 95
18. Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., Abdel-Meguid S., Adams J.L., and Goldsmith E.J. Structure 6 (1998) 1117
19. Lisnock J., Tebben A., Frantz B., O'Neill E.A., Croft G., O'Keefe S.J., Li B., Hacker C., De Laszlo S., Smith A., Libby B., Liverton N., Hermes J., and LoGrasso P. Biochemistry 37 (1998) 16573
20. Mavunkel, B. J.; Chakravarty, S.; Perumattam, J. J.; Dugar, S.; Lu, Q.; Liang, X. WO 2000/071535, 2000.
21. Mavunkel, B. J.; Perumattam, J. J.; Lu, Q.; Dugar, S.; Goyal, B.; Wang, D. X.; Chakravarty, S.; Luedtke, G. R.; Nashashibi, I.; Tester, R.; Tan, X. US Patent Application 2005/288299, 2005.
22. Nomura, M.; Takahashi, Y.; Tanase, T.; Miyachi, H.; Tsunoda, M.; Ide, T.; Murakami, K. WO 2000/ 075103, 2000.
23. Carter, J. S.; Obukowicz, M. G.; Devadas, B.; Talley, J. J.; Brown, D. L.; Graneto, M. J.; Bertenshaw, S. R.; Rogier, D. J., Jr.; Nagarajan, S. R.; Hanau, C. E.; Hartmann, S. J.; Ludwig, C. L.; Metz, S. WO 98/47890, 1998.
24. Büchi G., Lee G.C.M., Yang D., and Tannenbaum S.R. J. Am. Chem. Soc. 108 (1986) 4115
25. 50 was determined to be the concentration of compound which reduced the incorporation of ATP into the substrate by 50%, when compared with control reactions containing no inhibitor.
26. The LPS/TNFα Human Whole Blood Assay was run as described in: Mavunkel, B.; Dugar, S.; Luedtke, G.; Tan, X.; McEnroe, G. US Patent 6,696,443, 2004.